Celery
Last updated: Jul 31, 2026
Celery is a Tel Aviv fintech startup that provides an AI-assisted audit layer for payroll, revenue, and expense controls. Its platform analyzes uploaded or connected financial data to surface errors, leakage, policy exceptions, and other issues before they become costly losses.
Visit WebsiteCompany Overview
Celery addresses a specific finance-operations problem: payroll and revenue controls are often performed manually across spreadsheets, disconnected systems, and recurring review processes. Its product combines automated data ingestion, rule-based checks, anomaly detection, and workflow-oriented review so finance teams can investigate exceptions rather than recheck every record. The public product is organized around Payroll Guard and Profit Shield, with the company positioning the platform as a low-integration audit layer that can connect to or accept uploaded data and begin producing findings quickly.
The initial customer wedge is labor-intensive businesses, particularly healthcare providers with large workforces and complex overtime, PTO, bonus, and billing processes. Celery's site says it reviews approximately $30 million in payroll each week and presents case studies and testimonials from healthcare operators; CTech reported in 2025 that the technology was used by dozens of U.S. healthcare providers and had processed more than $550 million in payroll data. These are meaningful commercialization signals, but they are primarily company- or media-reported claims and should be validated through reference calls, retention data, cohort economics, and independent confirmation of savings. The company's low-integration approach may shorten deployment for mid-sized operators, while also creating questions about data normalization, repeatability across payroll systems, and the durability of its detection models.
The competitive set spans payroll and workforce-management suites, financial controls and spend-management products, audit and compliance software, and internal analytics built on a customer's existing ERP or payroll data. Celery can win where a customer has fragmented operational data and a clear cost of manual review, but the product must show a superior signal-to-noise ratio and measurable prevention of overpayments or revenue leakage. Incumbents can add anomaly detection, while horizontal analytics and robotic-process-automation tools can reproduce parts of the workflow. Defensibility is therefore more likely to come from proprietary operating data, domain-specific controls, integrations, customer workflow adoption, and verified savings than from a generic AI label.
Celery has credible early-stage commercial momentum: the company describes a 2024 paid pilot that saved a U.S. care business $151,000 in overtime costs, and CTech reported a $6.25 million seed round in May 2025, bringing reported total funding to $9 million. The official site also identifies co-founders Yuval Brot, Noam Slomianko, and Hillel Shalev and lists a Tel Aviv hiring presence. For national-security analysis, the direct case is limited. Financial-control automation could help defense contractors or other regulated organizations manage labor and project-cost leakage, but the core product is not a defense technology, cyber-defense capability, or mission system. Any defense relevance would require evidence of customers, compliance workflows, handling requirements, or deployment in defense supply chains; it should not be inferred from Israeli origin or a technical founder's background.
Strategic Fit Assessment
Celery has a credible fintech wedge, reported seed financing, named founders, public customer case studies, and an operating metric that suggests real workflow usage. Its commercial opportunity depends on converting claimed savings and review-volume growth into repeatable retention, expansion, and defensible unit economics. It is not marked as an internal dual-use priority signal because the public product is financial-controls software and no defense-specific customer, contract, certification, or mission application was established. Diligence should focus on net retention, false-positive rates, gross margin after data operations, security controls, customer concentration, and whether savings claims survive independent verification.
Strategic Value to U.S.-Israel Alliance
Celery could improve financial resilience and audit efficiency for labor-intensive organizations, including firms that participate in critical infrastructure or defense supply chains. That is an indirect strategic benefit, not evidence of a national-security capability. The strongest relevance is operational: reducing preventable payroll and revenue leakage, improving accountability, and helping smaller regulated operators establish repeatable controls without a large IT implementation. Strategic value would increase materially if the company demonstrated defense-supply-chain adoption, stronger compliance evidence, or integrations into mission-critical financial workflows.
Key Technologies
- AI-assisted anomaly detection across payroll, revenue, and expense records
- Automated payroll auditing for overtime, PTO, bonuses, and policy exceptions
- Revenue-leakage and unprofitable-customer analysis
- Rule-based financial controls and configurable policy checks
- File upload and low-integration data ingestion for fragmented finance systems
- Exception review dashboards and audit-oriented reporting
Use Cases & Applications
- Detecting payroll discrepancies before payment runs
- Finding overtime, PTO, bonus, and labor-policy exceptions in healthcare workforces
- Identifying missed billing, revenue leakage, and unprofitable customer relationships
- Reviewing financial controls across multi-site or labor-intensive operators
- Reducing spreadsheet-based manual audit work for finance and operations teams
- Providing an initial control layer for regulated or defense-supply-chain businesses, subject to diligence
- Prioritizing human investigation of high-value anomalies rather than reviewing every transaction
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile. The editorial policy explains how profiles are researched, where automated drafting is used, and how corrections work.
This record lists 5 public references used for company identity, status, positioning, or material-claim review.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- celeryway.com Public source used for profile verification.
- celeryway.com Public source used for profile verification.
- celeryway.com Public source used for profile verification.
- calcalistech.com Public source used for profile verification.
- walla.co.il Public source used for profile verification.
- Profile update timestamp Last updated in the Claw & Talon database on Jul 31, 2026.
Investor Lens
What this entry is
Private startup
Why it may matter
Celery may matter as a Fintech & Insurance entry with not currently an investable standalone company for Israeli technology research.
How an independent investor should read this
Not currently an investable standalone company. Read this profile as a starting point for independent verification, not as a recommendation or suitability assessment.
Evidence to verify
- Verify current status
- Verify traction
- Verify cap table/funding
- Verify customer concentration
Main investor questions
- Is the company currently active, independently financeable, and raising or not raising on terms you can verify?
- What customer, revenue, product, and technical evidence supports the company story?
- What valuation, cap table, rights, and follow-on assumptions would govern any private exposure?
- What evidence would change the thesis or show that the profile is stale?
What not to infer
- Inclusion does not imply endorsement.
- Inclusion does not imply allocation availability or current fundraising.
- Scores do not indicate investment suitability or expected returns.
- Strategic importance does not automatically imply venture return potential.
Diligence questions
- What evidence verifies Celery's current customer traction, deployment status, and revenue concentration?
- Which technical claims are independently demonstrable today, and which remain roadmap or pilot-stage assertions?
- Is there a credible national-security or public-sector use case, or is the company primarily a commercial technology asset?
- What regulatory, procurement, and buyer-adoption constraints could slow deployment in strategic or government-adjacent markets?
- Is the company a live venture opportunity, a mature strategic reference, an acquired asset, or primarily a market-mapping entry?
Related sector
See the Fintech & Insurance sector page for market context, related subcategories, and other Israeli companies in this part of the database.
Related companies
Need a diligence readout?
Use the profile and related checklists as a starting point. If the decision needs more context, request a company screen, founder-call prep, diligence memo, or sector readout.